QWM
REGN icon

QP Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

QP Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-310
Closed -$239K – 106
2025
Q4 		$239K Buy
+310
New +$211K 0.21% 92

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

QP Wealth Management's REGN Position: Q1 2026 in Review

QP Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 310 shares — an estimated $239K sold.

QP Wealth Management first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $239K in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • QP Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • QP Wealth Management sold 310 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $239K.
  • QP Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • QP Wealth Management's Regeneron Pharmaceuticals position peaked at $239K in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on QP Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.